Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,priceHint,shortName,exchange,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,exchangeDataDelayedBy,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,marketState,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 29, 2021) 4","Short Ratio (Jul 29, 2021) 4","Short % of Float (Jul 29, 2021) 4","Short % of Shares Outstanding (Jul 29, 2021) 4","Shares Short (prior month Jun 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,IDYA,240260000.0,32906000,,,-10947000,,-10947000,4828000,-6223000,-11051000,-11051000,,,,,,0,8756000,19807000,14979000,104000,,-10947000,-10947000,387215000.0,88141000.0,240260000.0,22135000.0,328401000.0,3000.0,-146954000.0,48014000.0,-4000.0,897000.0,90427000.0,35771000.0,-4000.0,9461000.0,279789000.0,38254000.0,183749000.0,1325000.0,2108000.0,-48803000,-6895000,-49381000,15986000,368000,15986000,-46325000,-12930000,444000,1597000,2503000,-578000,244018000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,24.56,1630526403,1.0599995,23.62,24.71,23.035,152327,3.4307594,0.16237022,808171328,-15.160494,3.3988376,15,America/New_York,EDT,-14400000,False,False,USD,2,"IDEAYA Biosciences, Inc.",NMS,-1.04,-23.615385,7.226,22.602571,1.957428,0.086602,21.12924,0,finmb_329719147,NasdaqGS,"IDEAYA Biosciences, Inc.",USD,263509,244714,13.4,1.2007169,11.16 - 26.0,-1.4400005,-0.055384636,11.16,26.0,1620626412,1628598600,1629117000,-1.14,-1.62,PRE,4.510636,23.035 - 24.71,23.5,0.0,0.0,8,9,us_market,1.92,,,26.0,11.16,22.6,21.13,263.51k,244.71k,32.91M,,25.77M,6.35%,64.78%,2.31M,6.34,6.72%,6.02%,1.52M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",-84.49%,-85.71%,-7.42%,-14.57%,35.54M,1.16,,-20.16M,-28.93M,-30.03M,-1.14,,274.18M,7.14,5.97M,2.49,7.82,7.23,51.96M,12.35M,Value,94080,Healthcare,75,7,5,"IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting IDE397, a methionine adenosyltransferase 2a inhibitor for patients with solid tumors having MTAP deletions; PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.",South San Francisco,650 443 6209,CA,8,1609372800,1625097600,7,United States,http://www.ideayabio.com,86400,7,7000 Shoreline Court,Biotechnology,Suite 350
t-1,IDYA,233126000.0,32906000,,,-9021000,,-9021000,4816000,-4319000,-9135000,-9135000,,,,,,0,7247000,16382000,11566000,114000,,-9021000,-9021000,369130000.0,92971000.0,233126000.0,25514000.0,326097000.0,3000.0,-136007000.0,52069000.0,,217000.0,136752000.0,36129000.0,,9642000.0,308158000.0,8080000.0,165569000.0,2922000.0,1281000.0,37438000,-5942000,36435000,42004000,-470000,42004000,64715000,-13724000,382000,-1045000,2372000,-1003000,272029000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,24.56,1630526403,1.0599995,23.62,24.71,23.035,152327,3.4307594,0.16237022,808171328,-15.160494,3.3988376,15,America/New_York,EDT,-14400000,False,False,USD,2,"IDEAYA Biosciences, Inc.",NMS,-1.04,-23.615385,7.226,22.602571,1.957428,0.086602,21.12924,0,finmb_329719147,NasdaqGS,"IDEAYA Biosciences, Inc.",USD,263509,244714,13.4,1.2007169,11.16 - 26.0,-1.4400005,-0.055384636,11.16,26.0,1620626412,1628598600,1629117000,-1.14,-1.62,PRE,4.510636,23.035 - 24.71,23.5,0.0,0.0,8,9,us_market,1.92,,,26.0,11.16,22.6,21.13,263.51k,244.71k,32.91M,,25.77M,6.35%,64.78%,2.31M,6.34,6.72%,6.02%,1.52M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",-84.49%,-85.71%,-7.42%,-14.57%,35.54M,1.16,,-20.16M,-28.93M,-30.03M,-1.14,,274.18M,7.14,5.97M,2.49,7.82,7.23,51.96M,12.35M,Value,94080,Healthcare,75,7,5,"IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting IDE397, a methionine adenosyltransferase 2a inhibitor for patients with solid tumors having MTAP deletions; PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.",South San Francisco,650 443 6209,CA,8,1609372800,1625097600,7,United States,http://www.ideayabio.com,86400,7,7000 Shoreline Court,Biotechnology,Suite 350
t-2,IDYA,198274000.0,32906000,,,-5135000,,-5135000,3800000,-1480000,-5280000,-5280000,,,,,,0,10571000,15851000,12051000,145000,,-5135000,-5135000,325250000.0,99995000.0,198274000.0,27631000.0,298269000.0,3000.0,-126986000.0,56172000.0,7000.0,188000.0,72037000.0,38640000.0,7000.0,9476000.0,288605000.0,,211548000.0,1877000.0,953000.0,-4375000,-7719000,-4554000,6949000,1325000,6949000,-9201000,-11596000,361000,-1877000,1449000,-179000,249965000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,24.56,1630526403,1.0599995,23.62,24.71,23.035,152327,3.4307594,0.16237022,808171328,-15.160494,3.3988376,15,America/New_York,EDT,-14400000,False,False,USD,2,"IDEAYA Biosciences, Inc.",NMS,-1.04,-23.615385,7.226,22.602571,1.957428,0.086602,21.12924,0,finmb_329719147,NasdaqGS,"IDEAYA Biosciences, Inc.",USD,263509,244714,13.4,1.2007169,11.16 - 26.0,-1.4400005,-0.055384636,11.16,26.0,1620626412,1628598600,1629117000,-1.14,-1.62,PRE,4.510636,23.035 - 24.71,23.5,0.0,0.0,8,9,us_market,1.92,,,26.0,11.16,22.6,21.13,263.51k,244.71k,32.91M,,25.77M,6.35%,64.78%,2.31M,6.34,6.72%,6.02%,1.52M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",-84.49%,-85.71%,-7.42%,-14.57%,35.54M,1.16,,-20.16M,-28.93M,-30.03M,-1.14,,274.18M,7.14,5.97M,2.49,7.82,7.23,51.96M,12.35M,Value,94080,Healthcare,75,7,5,"IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting IDE397, a methionine adenosyltransferase 2a inhibitor for patients with solid tumors having MTAP deletions; PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.",South San Francisco,650 443 6209,CA,8,1609372800,1625097600,7,United States,http://www.ideayabio.com,86400,7,7000 Shoreline Court,Biotechnology,Suite 350
t-3,IDYA,195429000.0,32906000,,,-4926000,,-4926000,3938000,-1058000,-4996000,-4996000,,,,,,0,8967000,13963000,10025000,70000,,-4926000,-4926000,317242000.0,105955000.0,195429000.0,44876000.0,301384000.0,3000.0,-121851000.0,46198000.0,35000.0,279000.0,81238000.0,54173000.0,35000.0,9610000.0,281337000.0,10158000.0,197445000.0,,1405000.0,-183338000,91526000,-183583000,27068000,2153000,27068000,-66305000,90210000,347000,-1877000,1110000,-245000,227164000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,24.56,1630526403,1.0599995,23.62,24.71,23.035,152327,3.4307594,0.16237022,808171328,-15.160494,3.3988376,15,America/New_York,EDT,-14400000,False,False,USD,2,"IDEAYA Biosciences, Inc.",NMS,-1.04,-23.615385,7.226,22.602571,1.957428,0.086602,21.12924,0,finmb_329719147,NasdaqGS,"IDEAYA Biosciences, Inc.",USD,263509,244714,13.4,1.2007169,11.16 - 26.0,-1.4400005,-0.055384636,11.16,26.0,1620626412,1628598600,1629117000,-1.14,-1.62,PRE,4.510636,23.035 - 24.71,23.5,0.0,0.0,8,9,us_market,1.92,,,26.0,11.16,22.6,21.13,263.51k,244.71k,32.91M,,25.77M,6.35%,64.78%,2.31M,6.34,6.72%,6.02%,1.52M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",-84.49%,-85.71%,-7.42%,-14.57%,35.54M,1.16,,-20.16M,-28.93M,-30.03M,-1.14,,274.18M,7.14,5.97M,2.49,7.82,7.23,51.96M,12.35M,Value,94080,Healthcare,75,7,5,"IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting IDE397, a methionine adenosyltransferase 2a inhibitor for patients with solid tumors having MTAP deletions; PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.",South San Francisco,650 443 6209,CA,8,1609372800,1625097600,7,United States,http://www.ideayabio.com,86400,7,7000 Shoreline Court,Biotechnology,Suite 350
